TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.02
−2.71%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.16
From 52W high−28.08%
Volume8.93M
Market cap$1.64B
P/E (TTM)—
P/S (TTM)298.2x
Div yield—
Key dataSep 18, 2026
Open
$5.16
From 52W high
−28.08%
Volume
8.93M
Market cap
$1.64B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.3x
P/E (TTM)
—
RSI (14)
32.8
MomentumView details →
1D Return
−2.71%
YTD Return
−8.94%
SummaryUpdated Jun 1, 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company founded in 2019 and based in Dallas, Texas. The company went public in September 2020 and focuses on developing gene therapies for rare monogenic diseases affecting the central nervous system. Taysha has established a strategic partnership with The University of Texas Southwestern Medical Center to advance transformative gene therapy treatments. The company is currently advancing its lead program TSHA-102 through Phase 1/2 clinical trials for Rett syndrome, having completed dosing of 10 patients with encouraging preliminary results.
Similar companies
Latest newsMore news →
Taysha Gene Therapies, Inc. held its Q2 2026 earnings call on August 11, 2026.39d agoTaysha Gene Therapies completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, and is preparing for a potential biologics license application submission.40d ago